Luminex Gets FDA OK for New Version of CYP2D6 Kit | GenomeWeb

NEW YORK (GenomeWeb News) – Luminex announced after the close of the market Monday that the US Food and Drug Administration has cleared for marketing a new version of its xTAG CYP2D6 kit.

The test identifies variations in the Cytochrome P450 2D6 gene, which can affect how a patient metabolizes certain drugs. According to Luminex, CYP2D6 metabolizes more than 25 percent of drugs on the market today, including cardiovascular drugs, anti-psychotics, anti-depressants, and pain medications, among others.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.